Hemodynamic Management and Outcome of Patients Treated for Cerebral Vasospasm with Intraarterial Nicardipine and/or Milrinone
Authors:
- Edward BittnerEBEdward Bittner
- Silvia PiviSPSilvia Pivi
- John J. A. MarotaJMJohn J. A. Marota
- 1 March 2010
- journal article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 110 (3) , 895-902
Abstract
Treatment or on outcome and consequences of the hemodynamic management. We tested 2 hypotheses: (1) intraarterial administration of nicardipine and milrinone to treat cerebral vasospasm would require increased administration of vasoconstrictor to support arterial blood pressure at target levels; and (2) high-dose vasopressors administered to increase blood pressure in these patients would lead to systemic acidosis and end-organ ischemic damage. METHODS: We conducted a single-center, retrospective review of consecutive patients with clinically symptomatic vasospasm after aneurysmal subarachnoid hemorrhage that failed medical management with “triple H therapy” and subsequently received intraarterial nicardipine and/or milrinone between March 2005 and July 2007. RESULTS: Of 160 endovascular interventions in 73 patients (aged 52 ± 10 years; 50 women), 96 received only nicardipine, 5 only milrinone, and 59 both drugs. General anesthesia with muscle relaxation was performed for 93% of procedures. During treatment, both the number and dose of vasopressors required to maintain arterial blood pressure at target levels increased; the median dose of phenylephrine increased from 200 (n = 121) to 325 μg/min (n = 122), norepinephrine increased from 12 (n = 60) to 24.5 μg/min (n = 87), and vasopressin infusions increased from 7 to 24. Nonetheless, arterial blood pressure decreased 13% during treatment. In >90% of procedures, the postprocedure angiogram showed improved vessel caliber. A single patient demonstrated troponin T increase; no patients had a decrease in renal function, bowel or peripheral ischemia, systemic acidosis, or acute stroke. Overall mortality was 11%. CONCLUSIONS: Intraarterial administration of nicardipine and/or milrinone requires use of vasopressors to maintain arterial blood pressure. Despite high doses of vasoconstrictors, treatment has low mortality, minimal end-organ ischemic damage or systemic acidosis, and results in improved caliber of cerebral vessels affected by vasospasm....Keywords
This publication has 18 references indexed in Scilit:
- Milrinone for the Treatment of Cerebral Vasospasm After Aneurysmal Subarachnoid HemorrhageStroke, 2008
- Anesthetic Considerations of Selective Intra-arterial Nicardipine Injection for Intracranial VasospasmJournal of Neurosurgical Anesthesiology, 2007
- Evidence-based cerebral vasospasm managementNeurosurgical Focus, 2006
- "Triple-H" Therapy for Cerebral Vasospasm Following Subarachnoid HemorrhageNeurocritical Care, 2006
- Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhageClinical Radiology, 2005
- Prediction of Cerebral Vasospasm in Patients Presenting with Aneurysmal Subarachnoid Hemorrhage: A ReviewNeurosurgery, 2005
- Practice parameters for hemodynamic support of sepsis in adult patients: 2004 updateCritical Care Medicine, 2004
- Milrinone Reduces Cerebral Vasospasm After Subarachnoid Hemorrhage of WFNS Grade IV or VNeurologia medico-chirurgica, 2004
- Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysisJournal of Neurosurgery, 1996
- Renovascular resistance and noradrenalineAmerican Journal of Physiology-Legacy Content, 1975